Download Files:

Bis(maltolato)oxovanadium(IV)

$50$380

Products Details

Product Description

– Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer[1][2].

Web ID

– HY-118567

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Metabolism-sugar/lipid metabolism

Molecular Formula

– C12H10O7V

References

– [1] Janine Krüger, et al. Inhibition of Src homology 2 domain-containing phosphatase 1 increases insulin sensitivity in high-fat diet-induced insulin-resistant mice. FEBS Open Bio. 2016 Jan 4;6(3):179-89.|[2]Kevin G Peters, et al. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. J Inorg Biochem. 2003 Aug 1;96(2-3):321-30.

CAS Number

– 38213-69-3

Molecular Weight

– 317.15

Compound Purity

– 99.34

SMILES

– O=[V+2]([O-]C1=C2C)([O]=C1C=CO2)([O]=C3C=CO4)[O-]C3=C4C

Clinical Information

– No Development Reported

Research Area

– Metabolic Disease

Solubility

– DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)

Target

– Phosphatase;SHP2

Pathway

– Metabolic Enzyme/Protease;Protein Tyrosine Kinase/RTK

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.